Buradasınız

THE IMPACT OF PATIENT COUNSELING ON THE QUALITY OF LIFE IN PATIENTS WITH TYPE II DIABETES MELLITUS

Share

Journal Name:

Publication Year:

Volume:

Number:

Page Number-First: 
1
Page Number-Last: 
12

Publication Language:

Abstract (2. Language): 
Background Diabetes mellitus has been identified as one of the major contribution of mortality worldwide. A comparative intervention (concurrent control) study was conducted to determine the influences of pharmaceutical care on quality of life in Type II diabetic patients. Materials and Method The study was carried out at the outpatient clinic of Hospital Kuala Lumpur, Malaysia for five months by convenience sampling where 140 patients were enrolled equally into control and intervention groups. Intervention group received counseling with information leaflet whereas control group was deprived of any pharmaceutical care till the end of the study. Follow up was done one month after baseline by telephone survey. Pre-validated Diabetes-39 questionnaire was administered at baseline and follow up. Clinical parameters such as fasting blood glucose, body mass index and HbA1c were compared between groups post counseling. Results Independent t-test and Chi-square test were conducted and intervention group showed a reduction in the effect of diabetes on quality of life. The changes in mean score was highest in energy and mobility domain, showing a decline from 56.53±17.80 at baseline to 49.57±17.12 at follow up (p<0.05). The clinical parameters revealed slight reduction in intervention group. However, the differences were not significant (p>0.05). There were no significant changes in scores and clinical outcomes for control group (p>0.05). Three domains were negatively associated with quality of life where energy and mobility has the strongest association. Conclusion The findings revealed that the intervention program was effective in enhancing Type II Diabetes patients' quality of life.

REFERENCES

References: 

1. King H, Aubert RE and Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
2. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047–1053.
3. Wong E, Backholer K, Harding J, Gearon E, Stevenson C, Freak-Poli R and Peeters A: A systematic review and meta-analysis of diabetes and risk of physical disability and functional impairment - protocol. Systematic Reviews 2012; 1-47.
4. Letchuman GR, Wan Nazaimoon WM, Wan Mohamad WB, Chandran LR, Tee GH, Jamaiyah H, Isa MR, Zanariah H, Fatanah I, Ahmad Faudzi Y: Prevalence of Diabetes in the Malaysian National Health Morbidity Survey III 2006. Medical Journal of Malaysia 2010; 65: 180-186.
5. Nabilla S. Direct costs of diabetes in an outpatient setting in Malaysia. National Committee for Clinical Research 2003, 2: 19-27.
6. Mafauzy M. Diabetes mellitus in Malaysia. Medical Journal of Malaysia 2006, 61: 397-398.
Research Article CODEN: IJPRNK ISSN: 2277-8713
Prabhu M, IJPRBS, 2015; Volume 4(1): 1-12 IJPRBS
Available Online at www.ijprbs.com
10
7. Mafauzy M. Diabetes control and complications in private primary health care in Malaysia. Medical Journal of Malaysia 2005; 60: 212-217.
8. Ismail M, Chee S, Nawawi H, Yusoff K, Lim T and James W. Obesity in Malaysia. Obesity Reviews 2002; 3: 203-208.
9. Donald A: What is Quality of Life? Hayward Medical Communication 2010, 1.
10. Maddigan SL, Feeny DH, Johnson JA: Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Quality of Life Research 2005; 14:1311-1320.
11. Saito, I. Inami, F. Ikebe, T. Moriwaki, C. Tsubakimoto, A. Yonemasu, K. (2006) Impact of Diabetes on Health-related Quality of Life in a Population Study in Japan. Diabetes Research and Clinical Practice, 73(1), 51-57.
12. Saito I, Inami F, Ikebe T, Moriwaki C, Tsubakimoto A, Yonemasu K, Ozawa H. Impact of Diabetes on Health-related Quality of Life in a Population Study in Japan. Diabetes Research and Clinical Practice 2006; 73: 51-57.
13. Rubin RR and Peyrot M. Quality of Life and Diabetes. Diabetes/Metabolism Research and Reviews 1999; 15: 205-218.
14. Peyrot M, Rubin R, Lauritzen T, Snoek FJ, Matthews DR and Skovlun SE. Psychosocial Problems and Barriers to Improved Diabetes Management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabetic Medicine 2005; 22: 1379-1385.
15. Hill-Briggs F, Gary TL, Baptiste-Roberts K and Brancati FL. Thirty-six-item Short Form Outcomes Following A Randomized Controlled Trial in Type 2 Diabetes. Diabetes Care 2005; 28: 443-444.
16. Bradley C and Speight B: Patient perceptions of diabetes and diabetes therapy: Assessing quality of life. Diabetes/Metabolism Research and Reviews 2002; 18: S64-S69..
17. Atak N and Arslan U: A Pilot Project to Develop and Assess a Health Education Programme for Type 2 Diabetes Mellitus Patients. Health Education Journal 2005; 64: 339-346.
18. Ramachandran A, Wan Ma RC and Snehalatha C: Diabetes in Asia. Lancet 2010; 375: 408-418.
19. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. The Journal of the American Medical Association 2009; 301: 2129-2140.
Research Article CODEN: IJPRNK ISSN: 2277-8713
Prabhu M, IJPRBS, 2015; Volume 4(1): 1-12 IJPRBS
Available Online at www.ijprbs.com
11
20. Lee JW, Brancati FL and Yeh HC: Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997-2008. Diabetes Care 2011; 34: 353-357.
21. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ and Birmingham CL: Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). The American Journal of Clinical Nutrition 2007; 86: 353-359.
22. Raji A, Seely EW, Arky RA and Simonson DC: Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. The Journal of Clinical Endocrinology and Metabolism 2001; 86(11): 5366-5371.
23. Chandalia M, Abate N, Garg A, Stray-Gundersen J and Grundy SM. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. The Journal of Clinical Endocrinology and Metabolism 1999; 84: 2329-2335.
24. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P and Son HY: Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
25. Shelgikar KM, Hockaday TD and Yajnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabetic Medicine 1991; 8: 712-717.
26. Koppes LL, Dekker JM, Hendriks HF, Bouter LM and Heine RJ. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 2005; 28: 719-725.
27. Freiberg MS, Cabral HJ, Heeren TC, Vasan RS and Curtis Ellison R: Alcohol consumption and the prevalence of the Metabolic Syndrome in the US.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2954-2959.
28. Rimm EB, Chan J, Stampfer MJ, Colditz GA and Willett WC: Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. British Medical Journal 1995; 310: 555–559.
29. Sultana G, Kapur P, Aqil M, Alam MS and Pillai KK. Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. Journal of Clinical Pharmacology and Therapeutics 2010; 35: 267–277.
Research Article CODEN: IJPRNK ISSN: 2277-8713
Prabhu M, IJPRBS, 2015; Volume 4(1): 1-12 IJPRBS
Available Online at www.ijprbs.com
12
30. Vengurlekar S, Shukla P, Patidar P, Bafna R and Jain S: Prescribing pattern of antidiabetic drugs in indore city hospital. Indian Journal of Pharmaceutical Sciences 2008; 70: 637-640.
31. Yurgin N, Secnik K and Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clinical Therapeutics 2007; 29: 316-325.
32. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z: Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Services Research 2006; 6: 159.
33. John LJ, Arifulla M, Sreedharan J, Muttappallymyalil J, DAS R, John J and Basha A: Age and gender-based utilisation pattern of antidiabetic drugs in Ajman, United Arab Emirates. Malaysian Journal of Pharmaceutical Sciences 2012; 10: 79-85.
34. Edelson GW and Sowers JR. Insulin resistance in hypertension: a focused review. The American Journal of the Medical Sciences 1993; 306: 345-347.
35. Sowers JR: Insulin resistance and hypertension. Mol Cell Endocrinol 1990; 74: C87-C89.
36. Dudzinska, M. Kurowska, M. Tarach, J. Chitryn, A. Barton. B. (2008) Social problems of diabetics. The influence of diabetes on patients’ daily, family and personal lives. Department of Endocrinology, 8(4): 150-156.
37. Anderson R, Grigsby A, Freedland K, Groot M, McGill J, Clouse R and Lustman P. Anxiety and poor glycemic control: a meta-analytic review of the literature. The International Journal of Psychiatry in Medicine 2002; 32: 235-247.

Thank you for copying data from http://www.arastirmax.com